Generate Biomedicines, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

GENB$14.18+8.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data) (unaudited)

	As of March 31,	As of December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$160,575	$121,650
Marketable securities	356,066	99,848
Restricted cash and cash equivalents (VIE)	-	339
Prepaid expenses and other current assets	18,749	12,528
Total current assets	535,390	234,365
Property and equipment, net	27,837	29,151
Operating lease right-of-use assets	57,765	59,860
Other assets	4,745	6,806
Total assets	$625,737	$330,182
Liabilities, convertible preferred stock, non-controlling interest and stockholders’ deficit
Current liabilities:
Accounts payable(1)	$7,617	$3,837
Accrued expenses and other current liabilities	19,267	42,164
Deferred revenue – current	17,244	21,194
Current portion of finance lease liabilities	3,883	4,311
Operating lease liabilities – current	10,378	10,697
Total current liabilities	58,389	82,203
Non-current liabilities:
Warrant to purchase convertible preferred stock	-	1,205
Finance lease liabilities, net of current portion	2,221	2,908
Deferred revenue – non-current	1,238	4,511
Operating lease liabilities – non-current	49,088	50,610
Other long term liabilities	-	116
Total liabilities	110,936	141,553
Commitments and contingencies (Note 13)
Convertible preferred stock	-	811,826
Non-controlling interest	-	(7,232)
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 500,000,000 and 200,456,735 shares authorized as of March 31, 2026 and December 31, 2025 respectively; 128,192,484 and 33,116,957 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	128	33
Additional paid-in capital	1,252,388	60,189
Accumulated other comprehensive income	24	106
Accumulated deficit	(737,739)	(676,293)
Total stockholders’ equity (deficit)	514,801	(615,965)
Total liabilities, convertible preferred stock, non-controlling interests and stockholders’ equity (deficit)	$625,737	$330,182

(1)

Includes related party amounts of $0.1 million for thethree months ended March 31, 2026, and $0.2 million for the year ended December 31, 2025. See Note 14 for details of related party amounts.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.